Avastin and Hypovolaemic shock for Men aged 60+ (a phase IV clinical study of FDA data)

Summary:

Hypovolaemic shock is found for men aged 60+ who take Avastin (bevacizumab). This study is created by eHealthMe based on reports of 14,031 men aged 60+ from the FDA, and is updated regularly. The information that eHealthMe analyzes includes:

  • Time on Avastin when people have Hypovolaemic shock
  • Top conditions
  • Top co-used drugs
  • Top other side effects


On Feb, 13, 2026

14,031 men aged 60+ reported to have side effects when taking Avastin.
Among them, 13 people (0.09%) have Hypovolaemic shock


What is Avastin?

Avastin has active ingredients of bevacizumab. It is often used in high blood cholesterol. eHealthMe is studying from 76,365 Avastin users. Check the latest studies of Avastin.

What is Hypovolaemic shock?

Hypovolaemic shock (shock caused by severe blood or fluid loss) is found to be associated with 531 drugs and 592 conditions by eHealthMe. Check the latest studies of Hypovolaemic shock.

Number of reports submitted per year:

Could Avastin cause Hypovolaemic shock in men aged 60+?

Time on Avastin when people have Hypovolaemic shock *

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Severity of Hypovolaemic shock

n/a

How people recovered from Hypovolaemic shock

n/a

Top conditions involved for these people *:

You may use this to check any potential undetected conditions.

  1. Colon Cancer: 10 people, 76.92%
  2. Tumor: 1 person, 7.69%
  3. Lung Adenocarcinoma Stage Iv (the cancer has spread to other organs of the body, such as the other lung, brain, or liver): 1 person, 7.69%
  4. Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 1 person, 7.69%

Top co-used drugs for these people *:

You may use this to check any potential interacting drugs.

  1. Oxaliplatin: 4 people, 30.77%
  2. Xeloda: 3 people, 23.08%
  3. Losartan Potassium: 3 people, 23.08%
  4. Dexamethasone: 1 person, 7.69%
  5. Carboplatin: 1 person, 7.69%
  6. Capecitabine: 1 person, 7.69%
  7. Alimta: 1 person, 7.69%
  8. Afinitor: 1 person, 7.69%

Top other side effects for these people *:

You may use this to check any potential undetected side effects.

  1. Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 8 people, 61.54%
  2. Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 8 people, 61.54%
  3. Erosive Duodenitis (a condition that affects the wall of the small intestine): 7 people, 53.85%
  4. Oesophagitis Ulcerative (inflammation of oesophagus with multiple ulcers): 5 people, 38.46%
  5. Acute Kidney Failure: 4 people, 30.77%
  6. Red Blood Cell Count Decreased: 3 people, 23.08%
  7. Gastrointestinal Toxicity (damage to digestive tract by any substance): 2 people, 15.38%
  8. Anorexia (eating disorder characterized by immoderate food restriction and irrational fear of gaining weight): 2 people, 15.38%
  9. Oesophageal Ulcer (ulcer of oesophagus): 2 people, 15.38%
  10. Dehydration (dryness resulting from the removal of water): 2 people, 15.38%

* Approximation only. Some reports may have incomplete information.

Do you take Avastin and have Hypovolaemic shock?

- Check whether Hypovolaemic shock is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.



Related studies:

How the study uses the data?

The study is based on (applicable) gender, age, bevacizumab (the active ingredients of Avastin) and Avastin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: